PRQR - ProQR Therapeutics N.V.
IEX Last Trade
2.79
0.040 1.434%
Share volume: 10,279
Last Updated: Fri 27 Dec 2024 08:30:00 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
0.25%
PREVIOUS CLOSE
CHG
CHG%
$2.75
0.04
1.45%
Fundamental analysis
24%
Profitability
25%
Dept financing
5%
Liquidity
50%
Performance
21%
Performance
5 Days
0.37%
1 Month
-26.98%
3 Months
46.45%
6 Months
62.42%
1 Year
33.33%
2 Year
-16.77%
Key data
Stock price
$2.79
DAY RANGE
$2.74 - $2.79
52 WEEK RANGE
$1.66 - $4.62
52 WEEK CHANGE
$35.35
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/14/2024
Company detail
CEO: Daniel Anton de Boer
Region: US
Website: proqr.com
Employees: 180
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: proqr.com
Employees: 180
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
ProQR Therapeutics N.V. engages in the discovery and development of RNA-based therapeutics. It is primarily developing sepofarsen that is in phase II/III illuminate trial for treating leber's congenital amaurosis 10 disease. It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University.
Recent news